adenine has been researched along with everolimus in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, CC; Chiu, TH; Huang, YT; Lai, PC; Lin, TC | 1 |
| Chang, J; Cheng, L; Ji, D; Li, J; Liu, R; Liu, X; Sun, Z; Wang, C; Wang, S; Wang, X; Zhang, X; Zhang, Z; Zheng, B; Zheng, R | 1 |
| Castillo, JJ; Ghobrial, IM; Treon, SP | 1 |
| Treon, SP | 1 |
| Bernasconi, E; Bertoni, F; Cascione, L; Cvitkovic, E; Gaudio, E; Odore, E; Ponzoni, M; Rezai, K; Rinaldi, A; Riveiro, E; Stathis, A; Tarantelli, C; Zucca, E | 1 |
| Hawkes, N | 1 |
| Ailawadhi, S; Ansell, SM; Bergsagel, PL; Braggio, E; Buadi, FK; Chanan-Khan, A; Colgan, JP; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Go, RS; Gonsalves, WI; Greipp, PT; Grogan, M; Habermann, TM; Hayman, SR; Hwa, YL; Inwards, DJ; Jevremovic, D; Johnston, PB; Kapoor, P; Ketterling, RP; King, RL; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Lust, JA; Markovic, SN; Mauermann, M; Micallef, IN; Mikhael, JR; Morice, WG; Novak, A; Nowakowski, GS; Porrata, LF; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Sher, T; Stewart, AK; Thompson, CA; Witzig, TE; Zeldenrust, SR | 1 |
| Bernasconi, E; Bertoni, F; Cascione, L; Chung, E; Gaudio, E; Haendler, B; Kwee, I; Lejeune, P; Mensah, AA; Ocker, M; Rinaldi, A; Schmees, N; Siegel, S; Spriano, F; Stathis, A; Tarantelli, C; Zucca, E | 1 |
| Till, BG | 1 |
3 review(s) available for adenine and everolimus
| Article | Year |
|---|---|
Biology, prognosis, and therapy of Waldenström Macroglobulinemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Everolimus; Humans; Piperidines; Prognosis; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy; Sirolimus; Stem Cell Transplantation; Waldenstrom Macroglobulinemia | 2015 |
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Everolimus; Humans; Myeloid Differentiation Factor 88; Piperidines; Plasma Exchange; Pyrazoles; Pyrimidines; Retreatment; Risk Assessment; Rituximab; Waldenstrom Macroglobulinemia | 2017 |
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Everolimus; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine; Young Adult | 2018 |
6 other study(ies) available for adenine and everolimus
| Article | Year |
|---|---|
Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.
Topics: Adenine; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; DNA Fragmentation; Drug Resistance, Neoplasm; Everolimus; Gemcitabine; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Microtubule-Associated Proteins; Naphthoquinones; Proto-Oncogene Proteins c-bcl-2; Securin; Sirolimus; Survivin; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms; Urothelium | 2014 |
The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Butadienes; Cell Line, Tumor; Chloroquine; Cyclin D1; Drug Synergism; Everolimus; Flavonoids; Gastric Mucosa; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Membrane Proteins; Microtubule-Associated Proteins; Mitogen-Activated Protein Kinases; Nitriles; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Topics: Acetanilides; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Everolimus; Heterocyclic Compounds, 3-Ring; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Rituximab; TOR Serine-Threonine Kinases; Vorinostat; Xenograft Model Antitumor Assays | 2016 |
NICE recommends dropping two drugs from Cancer Drugs Fund.
Topics: Adenine; Antineoplastic Agents; Cost-Benefit Analysis; England; Everolimus; Formularies as Topic; Humans; Piperidines; Pyrazoles; Pyrimidines; State Medicine | 2016 |
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
Topics: Adenine; Animals; Antineoplastic Agents; Benzodiazepines; Cell Death; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Everolimus; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Non-Hodgkin; Mice, SCID; Piperidines; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |